NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five ...

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") announced plans to change the ratio of its American Depository Shares ("ADSs") to its ...

Varda Space Industries has raised $187 million to accelerate drug development in space using microgravity technology.

Research reveals why EGFR-targeted cancer therapies often face resistance, leading to ongoing studies on combination treatments.

A study led by UCLA has discovered that JAK inhibitors could potentially prevent or reverse immune-related diabetes triggered ...